Lorraine Colón-Cartagena, MD
she/her/hers
Assistant Professor of PathologyCards
About
Research
Publications
2026
Quantitative Assays for TROP2 Measurement in Breast Cancer and Comparison to H-Score.
He M, Chan N, Liu M, Robbins C, Bates K, Benanto J, Colón-Cartagena L, Kahila M, Zhan H, Krishnamurti U, Moutafi M, Yaghoobi V, Liebler D, Fulton R, Rimm D. Quantitative Assays for TROP2 Measurement in Breast Cancer and Comparison to H-Score. Applied Immunohistochemistry & Molecular Morphology 2026 PMID: 41709478, DOI: 10.1097/pai.0000000000001311.Peer-Reviewed Original ResearchTrophoblast cell surface antigen 2Trophoblast cell surface antigen 2 expressionH-scoreBreast cancerQuantitative immunofluorescenceSacituzumab govitecanPathologists' readingsTNBC cohortAntibody-drug conjugate targetsExpression of trophoblast cell surface antigen 2H-score methodSolid tumor typesBreast cancer cohortBreast cancer biopsiesYale-New Haven HospitalBreast cancer samplesCompanion diagnostic testsSurface antigen 2H-score assessmentTumor typesClinical outcomesNew Haven HospitalCancer biopsiesTumor samplesCancer cohort
2025
Interobserver agreement and histologic analysis of atypical ductal hyperplasia bordering on ductal carcinoma in situ: A multi-institutional study
Korie U, Ai D, Podany P, Zhang H, Zhan H, Kahila M, Colon-Cartagena L, Wei S, Sun H, Du J, Krishnamurti U, Liang Y. Interobserver agreement and histologic analysis of atypical ductal hyperplasia bordering on ductal carcinoma in situ: A multi-institutional study. American Journal Of Clinical Pathology 2025, 164: 704-711. PMID: 40994034, DOI: 10.1093/ajcp/aqaf088.Peer-Reviewed Original ResearchConceptsDuctal carcinoma in situAtypical ductal hyperplasiaCarcinoma in situSpindle-shaped nucleiAssociated with carcinomaIndividual histologic featuresHistological featuresInterobserver agreementDuctal hyperplasiaBreast pathologistsBiopsy casesCases of atypical ductal hyperplasiaLow-grade ductal carcinoma in situEpithelial cellsClinical follow-up dataLesion extentHistological analysisDiagnostic gray zoneMulti-institutional studyVariable interobserver agreementFollow-up dataModerate to substantial agreementDuct involvementHistologic reviewRadiological findings116 Pathological and Molecular Characterization of Estrogen Receptor-Positive/HER2-Negative de novo Metastatic Breast Cancer
Babb P, Theriot J, Liang Y, Cartagena L, Buza N, Krishnamurti U, Zhan H. 116 Pathological and Molecular Characterization of Estrogen Receptor-Positive/HER2-Negative de novo Metastatic Breast Cancer. Laboratory Investigation 2025, 105: 102340. DOI: 10.1016/j.labinv.2024.102340.Peer-Reviewed Original Research214 Histologic Analysis and Clinical Correlation of Atypical Apocrine Lesions
Podany P, Zhan H, Cartagena L, Krishnamurti U, Liang Y. 214 Histologic Analysis and Clinical Correlation of Atypical Apocrine Lesions. Laboratory Investigation 2025, 105: 102438. DOI: 10.1016/j.labinv.2024.102438.Peer-Reviewed Original Research129 Unmasking Adenomyoepithelial Lesions of the Breast: A Review of 29 Cases
Cartagena L, Liang Y, Zhan H, Krishnamurti U. 129 Unmasking Adenomyoepithelial Lesions of the Breast: A Review of 29 Cases. Laboratory Investigation 2025, 105: 102353. DOI: 10.1016/j.labinv.2024.102353.Peer-Reviewed Original Research
2024
A Genomics-Driven Artificial Intelligence-Based Model Classifies Breast Invasive Lobular Carcinoma and Discovers CDH1 Inactivating Mechanisms.
Pareja F, Dopeso H, Wang Y, Gazzo A, Brown D, Banerjee M, Selenica P, Bernhard J, Derakhshan F, da Silva E, Colon-Cartagena L, Basili T, Marra A, Sue J, Ye Q, Da Cruz Paula A, Yeni Yildirim S, Pei X, Safonov A, Green H, Gill K, Zhu Y, Lee M, Godrich R, Casson A, Weigelt B, Riaz N, Wen H, Brogi E, Mandelker D, Hanna M, Kunz J, Rothrock B, Chandarlapaty S, Kanan C, Oakley J, Klimstra D, Fuchs T, Reis-Filho J. A Genomics-Driven Artificial Intelligence-Based Model Classifies Breast Invasive Lobular Carcinoma and Discovers CDH1 Inactivating Mechanisms. Cancer Research 2024, 84: 3478-3489. PMID: 39106449, PMCID: PMC11479818, DOI: 10.1158/0008-5472.can-24-1322.Peer-Reviewed Original ResearchConceptsInvasive lobular carcinomaBiallelic mutationsGenetic alterationsDiagnosing ILCGenotypic-phenotypic correlationsAI modelsBiological discoveryFusion geneCancer diagnosisCDH1Artificial intelligenceWhole-slide imagesInactivation mechanismLobular carcinomaMutationsHistological whole-slide imagesHistopathological featuresValidation cohortHistological featuresBreast neoplasmsHistological ground truthImprove cancer diagnosisGenomic and epigenomic basis of breast invasive lobular carcinomas lacking CDH1 genetic alterations
Dopeso H, Gazzo A, Derakhshan F, Brown D, Selenica P, Jalali S, Da Cruz Paula A, Marra A, da Silva E, Basili T, Gusain L, Colon-Cartagena L, Bhaloo S, Green H, Vanderbilt C, Oesterreich S, Grabenstetter A, Kuba M, Ross D, Giri D, Wen H, Zhang H, Brogi E, Weigelt B, Pareja F, Reis-Filho J. Genomic and epigenomic basis of breast invasive lobular carcinomas lacking CDH1 genetic alterations. Npj Precision Oncology 2024, 8: 33. PMID: 38347189, PMCID: PMC10861500, DOI: 10.1038/s41698-024-00508-x.Peer-Reviewed Original ResearchGenetic alterationsWhole-genome sequencingResistance to anoikisLoss-of-function mutationsCell adhesion genesBi-allelic inactivationEpigenomic basisAdhesion genesInvasive lobular carcinomaGenetic underpinningsMCF7 cellsCDH1 promoter methylationBreast invasive lobular carcinomaCDH1Genetic/epigenetic alterationsCellular migrationKnock-outE-cadherinPromoter methylationMutationsData reanalysisInactivationAXIN2 mutationsPhenotypeAxin2
2021
Pharmacological inhibition of MDA-9/Syntenin blocks breast cancer metastasis through suppression of IL-1β
Pradhan A, Maji S, Bhoopathi P, Talukdar S, Mannangatti P, Guo C, Wang X, Cartagena L, Idowu M, Landry J, Sarkar D, Emdad L, Cavenee W, Das S, Fisher P. Pharmacological inhibition of MDA-9/Syntenin blocks breast cancer metastasis through suppression of IL-1β. Proceedings Of The National Academy Of Sciences Of The United States Of America 2021, 118: e2103180118. PMID: 34016751, PMCID: PMC8166168, DOI: 10.1073/pnas.2103180118.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsBreast NeoplasmsCell Line, TumorChemokine CCL11Chemokine CCL17FemaleGene Expression Regulation, NeoplasticHumansInterleukin-10Interleukin-1alphaInterleukin-1betaInterleukin-23 Subunit p19Interleukin-5Lung NeoplasmsMiceMice, Inbred BALB COxadiazolesPyrimidinesSignal TransductionSynteninsT-Lymphocytes, CytotoxicTumor BurdenXenograft Model Antitumor AssaysConceptsMDA-9/SynteninMyeloid-derived suppressor cell differentiationSuppressor cell differentiationCancer cellsAdvanced disease stageAggressive breast cancerCytotoxic T lymphocytesMetastatic nodule formationBreast cancer metastasisBreast cancer pathogenesisMda-9/syntenin expressionCancer cell metastasisDirect therapeutic targetsCancer cell linesDiverse cancer cell linesPatient survivalDisease stageIL-1βSyndecan binding proteinBreast cancerInvasive cancer cellsT lymphocytesTherapeutic targetSmall molecule inhibitorsAdvanced stageBreast-Conserving Surgeries With and Without Cavity Shave Margins Have Different Re-excision Rates and Associated Overall Cost: Institutional and Patient-Driven Decisions for Its Utilization
Cartagena L, McGuire K, Zot P, Pillappa R, Idowu M, Robila V. Breast-Conserving Surgeries With and Without Cavity Shave Margins Have Different Re-excision Rates and Associated Overall Cost: Institutional and Patient-Driven Decisions for Its Utilization. Clinical Breast Cancer 2021, 21: e594-e601. PMID: 33814286, DOI: 10.1016/j.clbc.2021.03.003.Peer-Reviewed Original ResearchConceptsCavity shave marginsBreast-conserving surgeryRe-excision ratesRe-ExcisionPositive marginsInitial surgeryShave marginsPartial mastectomyEligible breast cancer patientsRate of margin positivityRate of positive marginsStandard partial mastectomySuperior surgical outcomesTissue volumeBreast cancer patientsBreast tissue volumeCavity shavingMarginal resectionMargin involvementLumpectomy specimensRetrospective reviewSurgical outcomesSingle surgeryClinical stagePresurgical diagnosisFalse-Positive 99mTechnetium-Pyrophosphate Scintigraphy in Two Patients With Hypertrophic Cardiomyopathy
Schafer E, Tushak Z, Trankle C, Rao K, Cartagena L, Shah K. False-Positive 99mTechnetium-Pyrophosphate Scintigraphy in Two Patients With Hypertrophic Cardiomyopathy. Circulation Heart Failure 2021, 14: e007558. PMID: 33663232, DOI: 10.1161/circheartfailure.120.007558.Peer-Reviewed Original ResearchMeSH KeywordsAmyloid Neuropathies, FamilialBiopsyBlack PeopleCardiomyopathiesCardiomyopathy, HypertrophicCarrier ProteinsFalse Positive ReactionsFemaleGenetic TestingHumansMagnetic Resonance ImagingMiddle AgedMyocardiumRadiopharmaceuticalsTechnetium Tc 99m PyrophosphateTomography, Emission-Computed, Single-PhotonConceptsHypertrophic cardiomyopathy
News
Get In Touch
Contacts
Email